Updates are available Correction dated 2026-03-19
Click to view Correction: https://doi.org/10.1038/s41391-026-01104-9
-
Authors
Siddiqui, Bilal A. https://orcid.org/0000-0002-6806-1294
Tawagi, Karine
Caulfield, Sarah
Aggarwal, Pankaj
Dorff, Tanya https://orcid.org/0000-0001-5990-298X
-
Funding
Funding for this research was provided by:
Johnson and Johnson
- License Information
-
More Information
Article History
Received: 1 October 2025
Revised: 26 January 2026
Accepted: 5 February 2026
First Online: 18 February 2026
Change Date: 16 March 2026
Change Type: Update
Change Details: In this article, in column 2, row 4 of Table 1 “Inducer (weak)” should be changed to “Inducer (strong)”.
Change Date: 19 March 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41391-026-01104-9
Competing interests
: Bilal A. Siddiqui has received consulting/advisory fees from Amgen, Bayer, Merck, Pfizer, Johnson & Johnson, SurvivorNet; honoraria fees from Cancer Expert Now, Curio Science, Cardinal Health, DAVA Oncology; researching funding (to individual) from ASCO-Conquer Cancer Foundation, Prostate Cancer Foundation, Cancer Research Institute; research funding (to institution) from Amgen, Johnson & Johnson, Regeneron; travel expenses from Merck, Curio Science, Cardinal Health. Karine Tawagi has received consulting/advisory fees from AstraZeneca, Seagen, Astellas, Pfizer; speaker fees from AstraZeneca; honoraria fees from GU Oncology Now, OncLive, Curio Science, Ideology Health, DAVA Oncology, Cardinal Health, Signify MD. Sarah Caulfield has nothing to disclose. Pankaj Aggarwal is a full-time employee and shareholder of Johnson & Johnson. Tanya Dorff has received consulting/advisory fees from Astellas, AstraZeneca, Bayer, Dendreon, Janssen, Pfizer, Novartis; research funding (to institution) from AbbVie, Amgen, AstraZeneca, Dendreon.
